Strength Training Plus Cardio Just Cut Diabetes Risk
A new meta-analysis published in Sports Medicine and reported by News-Medical.net found that combining strength training with aerobic exercise cuts Type 2 diabetes risk more than either modality alone. Across 35 studies and over 90,000 participants, the combination reduced Type 2 diabetes risk by 17–40% depending on dose, with the strongest effect at 150+ minutes […]
Lilly’s Oral GLP-1 Just Hit Its Numbers. It’s Still Not Reversal.
Eli Lilly’s oral GLP-1, orforglipron, just hit its primary endpoint in the first Phase 3 trial designed to support an FDA submission. The Lilly press release announced results from ACHIEVE-1, published in The New England Journal of Medicine, showing a 1.3%–1.6% A1c reduction and 6.8%–7.9% weight loss in adults with early Type 2 diabetes on […]
ADA 2026 Made Multimorbidity the Headline.
At the 2026 ADA Scientific Sessions in New Orleans, a team from Leicester launched a three-paper Lancet Series on cardiometabolic multimorbidity — and the agenda tells you exactly where the diabetes conversation is right now. What the Lancet Series Covers The Leicester/NIHR ARC East Midlands team presented three new papers in The Lancet on June […]
This New GLP-1 Pill Hit 89.6% A1c Goal — It Doesn’t Reverse Diabetes
The American Diabetes Association’s 2026 Scientific Sessions wrapped last week in New Orleans, and the headlines read like a victory lap. A new once-daily oral GLP-1 called elecoglipron — a small-molecule pill, no injection, no fasting window — sent 89.6% of patients in its phase 2b trial to an A1c of 7.0% or below. Up […]
Retatrutide Matches Bariatric Surgery: What Diabetics Should Know
New long-term data from the TRIUMPH-1 extension trial — presented at the American Diabetes Association’s 2026 Scientific Sessions — shows retatrutide drove an average of 30.3% body weight loss a 104 weeks, and 65% of participants dropped below the obesity threshold entirely. That puts a weekly injectable in the same conversation as gastric bypass and […]
Lilly’s GLP-1 Pill Just Beat Oral Ozempic – It Still Won’t Reverse Diabetes
The race for the first true GLP-1 pill just ended — and it wasn’t even close. Eli Lilly‘s once-daily oral GLP-1,orforglipron, just published head-to-head Phase 3 data showing it beat oral semaglutide (the pill form ofOzempic) on both A1c and weight loss. The results dropped this week in The Lancet, with a separate Phase 3study […]
The New GLP-1 Pill Won’t Reverse Your Type 2 Diabetes
AstraZeneca just reported phase 2 results for a new once-daily GLP-1 pill called elecoglipron. The numbers look great on the surface. The question the press is not asking: does it actually reverse the disease? What the New Study Shows AstraZeneca’s elecoglipron is a once-daily oral GLP-1 receptor agonist — the first of its kind in […]
Sleep Apnea and the Root Cause Conversation
The data is now a year old, but it has not been absorbed. In June 2024, the New England Journal of Medicine published the SURMOUNT-OSA trial results: tirzepatide, the GLP-1/GIP drug sold as Mounjaro and Zepbound, reduced sleep apnea severity by roughly 50% in adults with obesity. The 52-week, placebo-controlled study showed reductions in the […]
ADA 2026: New GLP-1 Drops A1c 2.2% — Now the Hard Question
The American Diabetes Association’s 86th Scientific Sessions wrapped last week in New Orleans, and the loudest headline came from Pfizer’s phase 2b VESPER-2 trial of berobenatide, a once-weekly and once-monthly GLP-1 showing a 2.2% A1c reduction and double-digit weight loss in people with Type 2 diabetes — with no plateau in sight. It’s a real […]
ADA 2026: The New “Miracle” Diabetes Drug Only Drops A1c 2%
The American Diabetes Association just unveiled the data everyone is talking about, and the headlines are loud. Eli Lilly’s retatrutide, a triple-hormone injection, dropped A1c by up to 2.0% and produced roughly 16.8% body-weight loss in adults with Type 2 diabetes. Pharma is calling it a breakthrough. Wall Street is calling it a blockbuster. The […]